Literature DB >> 23058073

The limit of plausibility for predictors of response: application to biventricular pacing.

Sukhjinder S Nijjer1, Punam A Pabari, Berthold Stegemann, Vittorio Palmieri, Francisco Leyva, Cecilia Linde, Nick Freemantle, Justin E Davies, Alun D Hughes, Darrel P Francis.   

Abstract

OBJECTIVES: We sought a method for any reader to quantify the limit, imposed by variability, to sustainably observable R(2) between any baseline predictor and response marker. We then apply this to echocardiographic measurements of mechanical dyssynchrony and response.
BACKGROUND: Can mechanical dyssynchrony markers strongly predict ventricular remodeling by biventricular pacing (cardiac resynchronization therapy)?
METHODS: First, we established the mathematical depression of observable R(2) arising from: 1) spontaneous variability of response markers; and 2) test-retest variability of dyssynchrony measurements. Second, we contrasted published R(2) values between externally monitored randomized controlled trials and highly skilled single-center studies (HSSCSs).
RESULTS: Inherent variability of response markers causes a contraction factor in R(2) of 0.48 (change in left ventricular ejection fraction [ΔLVEF]), 0.50 (change in end-systolic volume [ΔESV]), and 0.40 (change in end-diastolic volume [ΔEDV]). Simultaneously, inherent variability of mechanical dyssynchrony markers causes a contraction factor of between 0.16 and 0.92 (average, 0.6). Therefore the combined contraction factor, that is, limit on sustainably observable R(2) between mechanical dyssynchrony markers and response, is ~0.29 (ΔLVEF), ~0.24 (ΔESV), and ~0.30 (ΔEDV). Many R(2) values published in HSSCSs exceeded these mathematical limits; none in externally monitored trials did so. Overall, HSSCSs overestimate R(2) by 5- to 20-fold (p = 0.002). Absence of bias-resistance features in study design (formal enrollment and blinded measurements) was associated with more overstatement of R(2).
CONCLUSIONS: Reports of R(2) > 0.2 in response prediction arose exclusively from studies without formally documented enrollment and blinding. The HSSCS approach overestimates R(2) values, frequently breaching the mathematical ceiling on sustainably observable R(2), which is far below 1.0, and can easily be calculated by readers using formulas presented here. Community awareness of this low ceiling may help resist future claims. Reliable individualized response prediction, using methods originally designed for group-mean effects, may never be possible because it has 2 currently unavailable and perhaps impossible prerequisites: 1) excellent blinded test-retest reproducibility of dyssynchrony; and 2) response markers reproducible over time within nonintervened individuals. Dispassionate evaluation, and improvement, of test-retest reproducibility is required before any further claims of strong prediction. Prediction studies should be designed to resist bias.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23058073     DOI: 10.1016/j.jcmg.2012.07.010

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  11 in total

1.  Cardiac resynchronization therapy update: evolving indications, expanding benefit?

Authors:  C Butcher; Y Mareev; V Markides; M Mason; T Wong; J G F Cleland
Journal:  Curr Cardiol Rep       Date:  2015-10       Impact factor: 2.931

Review 2.  Effect of study design on the reported effect of cardiac resynchronization therapy (CRT) on quantitative physiological measures: stratified meta-analysis in narrow-QRS heart failure and implications for planning future studies.

Authors:  Richard J Jabbour; Matthew J Shun-Shin; Judith A Finegold; S M Afzal Sohaib; Christopher Cook; Sukhjinder S Nijjer; Zachary I Whinnett; Charlotte H Manisty; Josep Brugada; Darrel P Francis
Journal:  J Am Heart Assoc       Date:  2015-01-06       Impact factor: 5.501

3.  Difficulty in detecting discrepancies in a clinical trial report: 260-reader evaluation.

Authors:  Graham D Cole; Matthew J Shun-Shin; Alexandra N Nowbar; Kevin G Buell; Faisal Al-Mayahi; David Zargaran; Saliha Mahmood; Bharpoor Singh; Michael Mielewczik; Darrel P Francis
Journal:  Int J Epidemiol       Date:  2015-07-13       Impact factor: 7.196

4.  Defining the real-world reproducibility of visual grading of left ventricular function and visual estimation of left ventricular ejection fraction: impact of image quality, experience and accreditation.

Authors:  Graham D Cole; Niti M Dhutia; Matthew J Shun-Shin; Keith Willson; James Harrison; Claire E Raphael; Massoud Zolgharni; Jamil Mayet; Darrel P Francis
Journal:  Int J Cardiovasc Imaging       Date:  2015-07-04       Impact factor: 2.357

5.  Cardiac resynchronization therapy and AV optimization increase myocardial oxygen consumption, but increase cardiac function more than proportionally.

Authors:  Andreas Kyriacou; Punam A Pabari; Jamil Mayet; Nicholas S Peters; D Wyn Davies; P Boon Lim; David Lefroy; Alun D Hughes; Prapa Kanagaratnam; Darrel P Francis; Zachary I Whinnett
Journal:  Int J Cardiol       Date:  2013-10-16       Impact factor: 4.164

Review 6.  An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure.

Authors:  John G Cleland; William T Abraham; Cecilia Linde; Michael R Gold; James B Young; J Claude Daubert; Lou Sherfesee; George A Wells; Anthony S L Tang
Journal:  Eur Heart J       Date:  2013-07-29       Impact factor: 29.983

Review 7.  Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis.

Authors:  Alexandra N Nowbar; Michael Mielewczik; Maria Karavassilis; Hakim-Moulay Dehbi; Matthew J Shun-Shin; Siana Jones; James P Howard; Graham D Cole; Darrel P Francis
Journal:  BMJ       Date:  2014-04-28

8.  Evidence that conflict regarding size of haemodynamic response to interventricular delay optimization of cardiac resynchronization therapy may arise from differences in how atrioventricular delay is kept constant.

Authors:  S M Afzal Sohaib; Andreas Kyriacou; Siana Jones; Charlotte H Manisty; Jamil Mayet; Prapa Kanagaratnam; Nicholas S Peters; Alun D Hughes; Zachary I Whinnett; Darrel P Francis
Journal:  Europace       Date:  2015-04-07       Impact factor: 5.214

9.  Frequency of discrepancies in retracted clinical trial reports versus unretracted reports: blinded case-control study.

Authors:  Graham D Cole; Alexandra N Nowbar; Michael Mielewczik; Matthew J Shun-Shin; Darrel P Francis
Journal:  BMJ       Date:  2015-09-20

10.  Effects of Epicardial and Endocardial Cardiac Resynchronization Therapy on Coronary Flow: Insights From Wave Intensity Analysis.

Authors:  Simon Claridge; Zhong Chen; Tom Jackson; Kalpa De Silva; Jonathan Behar; Manav Sohal; Jessica Webb; Eoin Hyde; Matthew Lumley; Kal Asrress; Rupert Williams; Julian Bostock; Motin Ali; Jaswinder Gill; Mark O'Neill; Reza Razavi; Steve Niederer; Divaka Perera; Christopher Aldo Rinaldi
Journal:  J Am Heart Assoc       Date:  2015-12-17       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.